Takada Sayuri, Yata Yutaka, Ishizu Hirotaka, Inoue Yuma, Kuroda Tomoyasu, Ikeda Shigeki, Jogo Atsushi, Yamamoto Akira, Higashiyama Hiroshi, Kawada Norifumi
Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
Department of Hepatology, Osaka Metropolitan University, Osaka, Japan.
Case Rep Gastroenterol. 2025 Mar 20;19(1):173-183. doi: 10.1159/000544101. eCollection 2025 Jan-Dec.
We report an exceedingly rare case of hepatocellular carcinoma (HCC) associated with an idiopathic congenital forearm arteriovenous fistula (AVF). Given the absence of previous reports addressing the treatment of HCC in patients with AVF, we evaluate HCC treatment strategies, including the appropriateness of using angiogenesis inhibitors.
A 74-year-old man was admitted for the evaluation of liver tumors. His medical history included a chronic, intractable idiopathic right forearm AVF, for which he had undergone multiple surgical interventions. Abdominal EOB-MRI revealed multiple small focal lesions across both liver lobes during the hepatobiliary phase, indicative of multiple HCC, and liver biopsy confirmed early-stage HCC. Considering the potential presence of additional vascular anomalies similar to the forearm AVF, local hepatic artery chemoembolization was performed. Since there is still insufficient discussion about the systemic administration of angiogenesis inhibitors to patients with vascular abnormalities such as AVF, we discuss the treatment options for HCC with AVF, including its strategies in the progressed HCC stage.
As molecularly targeted therapies continue to evolve, recognizing the unique aspects of cases like ours is crucial. Establishing an appropriate treatment strategy for HCC patients with AVF is imperative, highlighting the need for tailored therapeutic approaches based on individual vascular profiles.
我们报告了一例极为罕见的肝细胞癌(HCC)合并特发性先天性前臂动静脉瘘(AVF)的病例。鉴于此前尚无关于AVF患者HCC治疗的报道,我们评估了HCC的治疗策略,包括使用血管生成抑制剂的适用性。
一名74岁男性因肝脏肿瘤评估入院。他的病史包括慢性、难治性特发性右前臂AVF,为此他接受了多次手术干预。腹部EOB-MRI在肝胆期显示两肝叶均有多个小局灶性病变,提示多发HCC,肝脏活检确诊为早期HCC。考虑到可能存在与前臂AVF类似的其他血管异常,遂进行了局部肝动脉化疗栓塞术。由于对于血管异常(如AVF)患者全身应用血管生成抑制剂的讨论仍不充分,我们探讨了AVF合并HCC的治疗选择,包括进展期HCC阶段的治疗策略。
随着分子靶向治疗不断发展,认识到我们此类病例的独特之处至关重要。为AVF合并HCC患者制定合适的治疗策略势在必行,这凸显了基于个体血管情况制定个性化治疗方法的必要性。